Literature DB >> 22622425

Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

Kim A Papp1, Cathy Reid2, Peter Foley3, Rod Sinclair3, David H Salinger4, Gary Williams5, Hua Dong6, James G Krueger7, Chris B Russell8, David A Martin9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22622425     DOI： 10.1038/jid.2012.163

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  51 in total

Review 1.  Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.

Authors:  Attia Attia; Abdelrahman Ibrahim Abushouk; Hussien Ahmed; Mohamed Gadelkarim; Ahmed Elgebaly; Zeinab Hassan; Mohamed M Abdel-Daim; Ahmed Negida
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

Review 2.  The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities.

Authors:  Ryan Rivera-Oyola; Roselyn Stanger; Graham H Litchman; Quinn Thibodeaux; John Koo; Richard Fried; Gary Goldenberg; George Han; Sylvia Hsu; Leon Kircik; Melissa Knuckles; Andrea Murina; Jeffrey Weinberg; Jashin J Wu; Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2020-12-01

Review 3.  Psoriasis: a mixed autoimmune and autoinflammatory disease.

Authors:  Yun Liang; Mrinal K Sarkar; Lam C Tsoi; Johann E Gudjonsson
Journal:  Curr Opin Immunol       Date:  2017-07-22       Impact factor: 7.486

4.  IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis.

Authors:  Iannis E Adamopoulos; Erika Suzuki; Cheng-Chi Chao; Dan Gorman; Sarvesh Adda; Emanual Maverakis; Konstantinos Zarbalis; Richard Geissler; Agelio Asio; Wendy M Blumenschein; Terrill Mcclanahan; Rene De Waal Malefyt; M Eric Gershwin; Edward P Bowman
Journal:  Ann Rheum Dis       Date:  2014-02-23       Impact factor: 19.103

5.  What is a pragmatic clinical trial?

Authors:  Hywel C Williams; Esther Burden-Teh; Andrew J Nunn
Journal:  J Invest Dermatol       Date:  2015-06       Impact factor: 8.551

6.  Clinical trials submitted to the JID: place your bet and show us your hand.

Authors:  Hywel C Williams; Barbara A Gilchrest
Journal:  J Invest Dermatol       Date:  2015-02       Impact factor: 8.551

7.  miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis.

Authors:  Helen Hermann; Toomas Runnel; Alar Aab; Hansjörg Baurecht; Elke Rodriguez; Nathaniel Magilnick; Egon Urgard; Liisi Šahmatova; Ele Prans; Julia Maslovskaja; Kristi Abram; Maire Karelson; Bret Kaldvee; Paula Reemann; Uku Haljasorg; Beate Rückert; Paulina Wawrzyniak; Michael Weichenthal; Ulrich Mrowietz; Andre Franke; Christian Gieger; Jonathan Barker; Richard Trembath; Lam C Tsoi; James T Elder; Eric R Tkaczyk; Kai Kisand; Pärt Peterson; Külli Kingo; Mark Boldin; Stephan Weidinger; Cezmi A Akdis; Ana Rebane
Journal:  J Invest Dermatol       Date:  2017-06-06       Impact factor: 8.551

8.  Brodalumab: First Global Approval.

Authors:  Sarah L Greig
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

9.  IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.

Authors:  Hye-Lin Ha; Hongshan Wang; Prapaporn Pisitkun; Jin-Chul Kim; Ilaria Tassi; Wanhu Tang; Maria I Morasso; Mark C Udey; Ulrich Siebenlist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 10.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.